Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 1, 2000 - Issue 7
Submit an article Journal homepage
70
Views
8
CrossRef citations to date
0
Altmetric
Review

Paediatric issues relating to the pharmacotherapy of allergic rhinitis

Eric J Schenkel Valley Clinical Research Center, 3729 Easton -Nazareth Highway, Ste 202, Easton, Pennsylvania 18045, USA.
Pages 1289-1306 | Published online: 24 Feb 2005

Bibliography

  • WRIGHT AL, HOLBERG CJ, MARTINEZ FD, HALONEN M, MORGAN W, TAUSSIG LM: Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics (1994) 94:895–901.
  • JONES NS, CAREY AS, DAVIS A: The prevalence of allergic rhinosinusitis: a review. j Laryngol. Otol. (1998) 112:1019–1030.
  • STRACHAN D, SIBBALD B, WEILAND S et al: Worldwide variations in the prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr. Allergy Immunol. (1997) 8:161–176.
  • VON MUTIUS E, MARTINEZ FD: Epidemiology of childhood asthma. In: Lung Biology In Health And Disease: Pediatric Asthma. Murphy S, Kelly HVV (Eds.) Marcel Dekker, New York, USA. 1–39.
  • HOLGATE S: The epidemic of allergy and asthma. Nature (1999) 402 (Suppl.):B2–B4.
  • VON MUTIUS E: The environmental predictors of allergic disease. J. Allergy Clin. Immunol. (2000) 105:9–19.
  • ••A new and comprehensive review of interactions betweenthe immune system and environmental factors.
  • COOKSON W: The alliance of genes and environment in asthma and allergy. Nature (1999) 402 (Suppl.) :B5–B11.
  • MELTZER E: Treatment options for the child with allergic rhinitis. Clin. Pediatr. (1998) 37:1–10.
  • BRAUN-FAHRLANDER C, WUTHRICH B et al.: Validation of a rhinitis symptom questionnaire (ISAAC core questions) in a population of Swiss school children visiting the school health services. SCARPOL-team. Pediatr. Allergy Iminunol. (1997) 8:75–82.
  • JONES NS, CARNEY AS, DAVIS A: The prevalence of allergic rhinosinusitis: a review. j Laryngol. Otol. (1998) 112:1019–1030.
  • •Comprehensive data on allergic rhinits prevalence.
  • BARNES K, MARSH D: The genetics and complexity of allergy and asthma. Immunol. Today (1998) 19:325–332.
  • FOLKERTS G, WALZL G, OPENSHAW PJM: Do common childhood infections 'teach' the immune system not to be allergic? Immunol Today (2000) 21:118–120.
  • ROOK GAW, STANFORD JL: Give us this day our daily germs. Immunol. Today (1998) 19:113–116.
  • •Two papers with stimulating discussion of aspects of the 'hygiene hypothesis'.
  • WILLIAMS CMM, GALLI SJ: The diverse potential effector and immunoreg-ulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. (2000) 105:847–859.
  • GLEICH GJ: Mechanisms of eosinophil-associated inflammation. J. Allergy Clin. Immunol. (2000) 105:651–663.
  • DURHAM SR: Mechanisms of mucosal inflammation inthe nose and lungs. Clin. Exp. Allergy (1998) 28 (Suppl. 2):11–16.
  • ROMAGNANI S: The role of lymphocytes in allergic disease. J. Allergy Clin. Immunol. (2000) 105:399–408.
  • ••Four well written views of different cellular and tissueprocesses involved in allergic rhinits.
  • NACLERIO R: Clinical manifestations of the release of histamine and other inflammatory mediators. J. Allergy Clin. Immunol. (1999) 103:S382–S385.
  • DURHAM SR, YING S, VARNEY VA et al.: Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after allergen provocation: relation-ship to tissue eosin ophilia. J. Immunol. (1992) 148:2390–2394.
  • BENSON M, STRANNEGARD IL, WENNERGREN G, STRANNEGARD 0: Cytokines in nasal fluids from school children with seasonal allergic rhinitis. Pediatr. Allergy Immunol (1997) 8:143–149.
  • MINSHALL E, CAMERON L, LAVIGNE F et al.: Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am. J. Respir. Cell Mot. Biol. (1997) 17:683–690.
  • RATAKULASINGAM K, HAMID Q, O'BRIEN F et al.: RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am. J. Respir. Grit. Care Med. (1997) 155:696–703.
  • BOCHNER BS, SCHLEIMER RP: The role of adhesionmolecules in human eosinophil and basophil recruit-ment. J. Allergy Clin. Immunol (1994) 94:427–438.
  • CHRISTODOULOPOULOS P, CAMERON L, DURHAM S, HAMID Q: Molecular pathology of allergic disease II: upper airway disease. J. Allergy Clin. Immunol. (2000) 105:211–223.
  • GROSSMAN J: One airway, one disease. Chest (1997) 111 (Suppl.):S11–S16.
  • VIGNOLA AM, CHANEZ P, GODARD P, BOUSQUET J: Relationships between rhinitis and asthma. Allergy (1998) 53:833–839.
  • SPECTOR SL: Overview of comorbid associations of allergic rhinitis. J. Allergy Clin. Immunol. (1997) 99:S773–S780.
  • PEAT JK, SALOME CM, WOOLCOCK AJ: Longitudinal changes in atopy during a 4-year period: relation to bronchial hyperresponsiveness and respiratory symptoms in a population sample of Australian schoolchildren. J. Allergy Clin. Immunol. (1990) 85:65–74.
  • AUBIER M, LEVY J, CLERICI C, NEUKIRCH F, CABRIERES F, HERMAN D: Protective effect of theophylline on bronchial hyp err esponsiveness in patients with allergic rhinitis. Am. Rev. Respir. Dis. (1991) 143:346–350.
  • CORREN J: Allergic rhinitis and asthma: how important is the link? J. Allergy Clin. Immunol. (1997) 99:S781–S786.
  • REISMAN RE, BERNSTEIN J: Allergy and secretory otitismedia: clinical and immunologic studies. Pediatr. Clin. North Am. (1975) 22(1):251–257.
  • KJELLMAN NI, SYNNERSTAD B, HANSSON LO: Atopic allergy and immunoglobulins in children with adenoids and recurrent otitis media. Acta Paediatr. Scand. (1976) 65(5):593–600.
  • BERNSTEIN JM: The role of IgE-mediated hypersensi-tivity in the development of otitis media with effusion: a review. Otolaryngol. Head Neck Surg. (1993) 109(3 Pt 2):611–620.
  • ICHIMIYA I, KAWAUCHI H, MOGI G: Analysis of immunocompetent cells in the middle ear mucosa. Arch. Otolaryngol. Head Neck Surg. (1990) 116(3) :324–330.
  • HURST DS, AMIN K, SEVEUS L, VENGE P: Evidence of mast cell activity in the middle ears of children with otitis media with effusion. Laryngoscope (1999) 109 (3):471–477.
  • DOYLE WJ, TAKAHARA T, FIREMAN P: The role of allergy in the pathogenesis of otitis media with effusion. Arch. Otolaryngol. (1985) 111 (8) :502–506.
  • BIKHAZI P, RYAN AF: Expression of immunoregulatory cytokines during acute and chronic middle ear immune response. Laryngoscope (1995) 105 (6):629–634.
  • HURST DS, VENGE P: The presence of eosinophil cationic protein in middle ear effusion. Otolaryngol. Head Neck Surg. (1993) 108(6):711–722.
  • YELLON RF, LEONARD G, MARUCHA P et al.: Demonstra-tion of interleukin 6 in middle ear effusions. Arch. Otolaryngol. Head Neck Surg. (1992) 118 (7) :745–748.
  • OSUR SL, VOLOVITZ B, DICKSON S, ENCK DC, BERNSTEIN JM: Eustachian tube dysfunction in children with ragweed hayfever during natural pollen exposure. Allergy Proc. (1989) 10 (2) :133–139.
  • SKONER DP, DOYLE WJ, CHAMOVITZ AH, FIREMAN P.Eustachian tube obstruction after intranasal challenge with house dust mite. Arch. Otolaryngol. Head Neck Surg. (1986) 112(8):840–842.
  • BOUSQUET J, LOCKEY R, MALLING H: WHO PositionPaper. Allergen Immunotherapy: Therapeutic vaccines for allergic diseases. Allergy (1998) 53 (Suppl. 54).
  • BASCOM R, WACHS M, NACLERIO RM, PIPKORN U, GALLISJ, LICHTENSTEIN LM: Basophil influx occurs after nasal antigen challenge: effects of topical corticos-teroid pretreatment. J. Allergy Clin. Iminunol. (1988) 81 (3) :580–589.
  • KLEMENTSSON H, SVENSSON C, ANDERSSON M, VENGE P, PIPKORN U, PERSSON CGA: Eosinophils, secretory responsiveness and glucocorticoid-induced effects on the nasal mucosa during a weak pollen season. Clin. Exp. Allergy (1991) 21:705–710.
  • HER E, FRAZER J, AUSTEN KF, OWEN WF: Eosinophil hematopoetins antagonize the programmed cell death of eosinophils: cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell containing medium. J. Clin. Invest. (1992) 88:1982–1987.
  • MULLOL J, XAUBET A, LOPEZ E, ROCA-FERRER J, PICADO C: Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax (1995) 50 (3):270–274.
  • RAK S, JACOBSON MR, SUDDERICK RM et al.: Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin. Exp. Allergy (1994) 24 (10):930–939.
  • MELTZER EO: Nasal cytological changes following pharmacological intervention. Allergy (1995) 50 (Suppl. 23):15–20.
  • MASUYAMA K, JACOBSON MR, RAK S et al.: Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology (1994) 82 (2) :192–199.
  • GHAFFAR O, LABERGE S, JACOBSON MR et al.: IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. Am. J Respir. Cell Mol. Biol. (1997) 17(0:17–24.
  • NELSON HS: Mechanisms of intranasal steroids in themanagement of upper respiratory allergic diseases. J Allergy Clin. Immunol (1999) 1 0 4:S138–S143.
  • JULIUSSON S, HOLMBERG K, KARLSSON G, ENERBACK L,PIPKORN U: Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid. Clin. Exp. Allergy (1993) 23(7):591–599.
  • NACLERIO RM, ADKINSON N, Jr., CRETICOS PS,BAROODY FM, HAMILTON RG, NORMAN PS: Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. J. Allergy Clin. Immunol. (1993) 92(5):717–721.
  • PIPKORN U, PROUD D, LICHTENSTEIN LM, KAGEY-SOBOTKA A, NORMAN PS, NACLERIO RM: Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl. J. Med. (1987) 316 (24):1506–1510.
  • •An early report of the anti-allergic effects of nasal steroid therapy.
  • SMITH CL, KREUTNER W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active gluco corticoids. Arzneim-Forsch/Drug Res. (1998) 48:956–960.
  • JOHNSON M: Development of fluticasone proprionate and comparison with other inhaled corticosteroids. Allergy Clin. Immunol (1998) 101 :S434–5439.
  • CORREN J: Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin. Immunol. (1999) 1 0 4:S144–S149.
  • BRANNAN MD, HERRON JM, AFFRIME MB: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Ther. (1997) 19 (6):1330–1339.
  • LAFORCE C: Use of nasal steroids in managing allergic rhinitis. J. Allergy Clin. Immunol. (1999) 103:388–394.
  • LAFORCE C, DAVIS V: Nasal septal perforation in patients using intranasal beclomethasone depropri-onate (sic). J. Allergy Clin. Immunol. (1985) 75:186. Abstract.
  • MINSHALL E, GHAFFAR 0, CAMERON L et al.: Assessmentby nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. (1998) 1 1 8 (5):648–654.
  • PIPKORN U, PUKANDER J, SUONPAA J, MAKINEN J, LINDQVIST N: Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin. Allergy (1988) 18 (3):253–259.
  • WISEMAN LR, BENFIELD P: Intranasal fluticasonepropionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs (1997) 53(5):885–907.
  • AGERTOFT L, WOLTHERS OD, FUGLSANG G, PEDERSEN S: Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr. Allergy Immunol (1993) 4(3):152–156.
  • KNUTSON U, STIERNA P, MARCUS C, CARLSTEDT-DUKE J, CARLSTROM K, BRONEGARD M: Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol. (1995) 144:301–310.
  • WILSON AM, SIMS EJ, MCFARLANE LC, LIPWORTH BJ: Effects of intranasal corticosteroids on adrenal, bone and blood markers of systemic activity in allergic rhinitis. J. Allergy Clin. Immunol. (1998) 102:598–604.
  • WILSON AM, MCFARLANE LC, LIPWORTH BJ: Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin. Immunol. (1998) 101(4 Pt 0:470–474.
  • BRANNAN MD, HERRON JM, REIDENBERG P, AFFRIME MB: Lack of HPA axis suppression following 36 days of intranasal mometasone furoate. Ann. Allergy Asthma Immunol. (1997) 78:154 Abstract.
  • WOLTHERS OD, PEDERSEN S: Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticoster-oids. Acta Paediatr. (1993) 82 (8):635–640.
  • SCHENKEL EJ, SKONER DP, BRONSKY EA et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate. Pediatrics (2000) 105(2):E22.
  • SKONER DP, RACHELEFSKY GS, MELTZER EO et al.: Detection of growth suppression in children during treatment with intranasal beclomethasone dipropri-onate. Pediatrics (2000) 105 (2):E23.
  • NAYAK AS, ELLIS MH, GROSS GN et al.: The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J. Allergy Clin. Immunol. (1998) 1 01 (2 Pt 0:157–162.
  • SIEGEL SC: Topical intranasal corticosteroid therapy. J Allergy Clin. Immunol (1988) 81:984–991.
  • BERKOWITZ RB, BERNSTEIN DI, LAFORCE C et al.: Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy (1999) 54 (1):64–69.
  • JEN A, BAROODY F, DETINEO M, HANEY L, BLAIR C, NACLERIO R: As-needed use of fluticasone proprionate nasal spray reduces symptoms of seasonal allergic rhinitis. J. Allergy Clin. Immunol (2000) 105:732–738.
  • GRAFT D, AARONSON D, CHERVINSKY P et al.: A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin. Immunol (1996) 98(4):724–731.
  • SIMONS FER, BERGMAN JN, WATSON WTA, SIMONS KJ: The clinical pharmacology of fexofenadine in children. J. Allergy Clin. Immunol. (1996) 98:1062–1064.
  • SIMONS FER, JOHNSTON L, SIMONS KJ: Clinical pharma-cology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatr. Allergy Immunol. (2000) 11:116–119.
  • ANTHES JC, RICHARD C, WEST RE et al.: Functionalcharacterization of desloratadine and other antihista-mines in a Chinese hamster ovary (CHO) cell line that expresses the cloned human H1 receptor and in human bronchial smooth muscle cells (HBSMC). Allergy Clin. Immunol (2000) 105:S384. Abstract 1125.
  • SALMUN LM, LORBER R, DANZIG M, STAUDIGER H: Efficacy and safety of desloratadine in seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 105:S384. Abstract 1123.
  • NAYAK A, LROBER R, SALMUN LM: Decongestant effectsof desloratadine in patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 105:S384. Abstract 1122.
  • KAY GG: The effects of antihistamines on cognitionand performance. J. Allergy Clin. Immunol. (2000) 105:622–627.
  • •Good review of current cognitive effects of available antihistamines.
  • VUURMAN EF, VAN-VEGGEL LM, UITERWIJK MM, LEUTNER D, O'HANLON JF: Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy (1993) 71 (2) :121–126.
  • ••Landmark research demonstrating disease-related learningimpairment, the negative effects of sedating antihistamines and the benefits of second-generation compounds.
  • VUURMAN EF, VAN-VEGGEL LM, SANDERS RL, MUNTJEW-ERFF ND, O'HANLON JF: Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. (1996) 76(3):247–252.
  • YAP YG, CAMM AJ: Arrhythmogenic mechanisms of non-sedating antihistamines. Clin. Exp. Allergy (1999) 29 (Suppl. 3):174–181.
  • •Useful overview of pharmacological/receptor mechanisms for QTc prolongation with some antihistamines.
  • TAGLIALATELA M, CASTALDO P, PANNACCIONE A et al.: Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin. Exp. Allergy (1999) 3:182–189.
  • BERUL CI, MORAD M: Regulation of potassium channels by non-sedating antihistamines. Circulation (1995) 91 (8):2220–2225.
  • ROY M, DUMAINE R, BROWN AM: HERG, a primary human ventricular target of the non-sedating antihis-tamine terfenadine. Circulation (1996) 94 (4):817–823.
  • GOSS JE, RAMO BW, BLAKE K: Torsades de pointes associated with astemizole (Llismanal) therapy [letter]. Arch. Intern. Med. (1993) 153 (23):2705.
  • ZIMMERMANN M, DURUZ H, GUINAND 0 et al.: Torsadesde Pointes after treatment with terfenadine and ketoconazole. Eur. Heart J. (1992) 13(7):1002–1003.
  • POHJOLA-SINTONEN S, VIITASALO M, TOIVONEN L, NEUVONEN P: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. j Clin. Pharmacol (1993) 45 (2):191–193.
  • PARIS DG, PARENTE TF, BRUSCHETTA HR, GUZMAN E,NIARCHOS AP: Torsades de pointes induced by erythromycin and terfenadine. Am. J. Emerg. Med. (1994) 12 (6):636–638.
  • BRANNAN MD, REIDENBERG P, RADWANSKI E et al.:Loratadine administered concomitantly with erythro-mycin: pharmacokinetic and electrocardiographic evaluations. Clin. Pharmacol. Ther. (1995) 5 8 (3) :269–278.
  • BERNSTEIN DI, SCHOENWETTER WF, NATHAN RA, STORMS W, AHLBRANDT R, MASON J: Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol (1997) 79(5):443–448.
  • PRATT CM, MASON J, RUSSELL T, REYNOLDS R, AHLBRANDT R: Cardiovascular safety of fexofenadine HC1. Am. J. Cardiol. (1999) 83(10):1451–1454.
  • BANFIELD C, PADHI D, GLUE P, HERRON JM; STATKEVICH P, AFFRIME MB: Electrocardiographic effects of multiple high doses of desloratadine. Allergy Clin. Immunol. (2000) 105(1 Pt 2):S383. Abstract.
  • GLUE P, BANFIELD C, AFFRIME MB, STATKEVICH P,REYDERMAN L, PADHI D: Desloratadine and erythro-mycin: Ph armacokinetics and electrocardiographic pharmacodynamic effects. J. Allergy Clin. Immunol (2000) 105(1 Pt 2):5387. Abstract.
  • AFFRIME MB, BANFIELD C, GLUE P, KEUNG A, HERRONJM, PADHI D: Desloratadine and ketoconazole: Pharmacokinetics and electrocardiographic pharma-codynamic effects. J. Allergy Clin. Immunol. (2000) 105(1 Pt 2):S386. Abstract.
  • MONROE EW, DALY AF, SHALHOUB RF: Appraisal of thevalidity of histamine induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Immunol. (1997) 99:S798–S806.
  • DAY JH, BRISCOE MP, CLARK RH, ELLIS AK, GERVAIS P: Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann. Allergy Asthma Immunol. (1997) 79 (2):163–172.
  • DAY JH, BRISCOE MP, WELSH A et al.: Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environ-mental exposure unit. Ann. Allergy Asthma Immunol. (1997) 79(6):533–540.
  • JANSSENS MM. LEVOCABASTINE: A new topical approach for the treatment of paediatric allergic rhinoconjunctivitis. Rhinology (1992) 13:S39–S49.
  • FALCONIERI P, MONTELEONE AM, MANCUSO T et al.: Effectiveness of levocabastine eye drops in children with allergic conjunctivitis: a double-blind study. Pediatr. Asthma Allergy Immunol. (1994) 8:111–115.
  • GASTPAR H, NOLTE D, AURICH R et al.: Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy (1994) 49:152–158.
  • ANDERSSON KE, BENDE M: Adrenoceptors in the control of human nasal mucosal blood flow. Ann. Otol. Rhino]. Laryngol. (1984) 93(2 Pt 1):179–182.
  • JOHNSON DA, HRICIK JG: The pharmacology of alpha-adr en er gic decongestants. Pharmacotherapy (1993) 13(6 Pt 2):110S-5S; Discussion 43S–46S.
  • BRONSKY E, BOGGS P, FINDLAY S et al.: Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin. Immunol. (1995) 96 (2):139–147.
  • MC DOWELL MK, SPITZ E: Treatment of chronic perennial allergic rhinitis a double blind trial of cromolyn sodium. Ann. Allergy (1977) 39:169–174.
  • ORGEL HA, MELTZER EO, KEMP JP, OSTROM NK, WELCH MJ: Comparison of intranasal cromolyn sodium, 4%, and oral terfenadine for allergic rhinitis: symptoms, nasal cytology, nasal ciliary clearance, and rhinoma-nometry. Ann. Allergy (1991) 66 (3):237–244.
  • WELSH PW, STRICKER WE, CHU CP et al.: Efficacy of beclomethasone nasal solution flunisolide and cromolyn in relieving symptoms of ragweed allergy. Mayo. Clin. Proc. (1987) 62:125–134.
  • BOUSQUET J, CHANAL I, ALQUIE MC et al.: Prevention of pollen rhinitis symptoms: comparison of fluticasone proprionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study. Allergy (1993) 48:327–333.
  • SCHULLER DE, SELCOW JE, JOOS TH et al: A multicenter trial of nedocromil sodium, 1 percent nasal solution, compared with cromolyn sodium and placebo in ragweed seasonal allergic rhinitis. J. Allergy Clin. Immunol. (1990) 86:554–561.
  • WOOD CC, FIREMAN P, GROSSMAN J, WECKER M, MACGREGOR T: Product characteristics and pharma-cokinetics of intranasal ipratropium bromide. J. Allergy Clin. Immunol. (1995) 95(5 Pt 2):1111–1116.
  • ANGGARD A: Parasympathetic influence on the nasal mucosa. Acta Otolmyngol. (1977) 83 (1-2):22–24.
  • GROTH S, DIRKSEN H, MYGIND N: The absence of systemic side-effects from high doses of ipratropium in the nose. Eur. j Respir. Dis. (Suppl.) (1983) 128 (Pt 2)490–493.

Websites

  • http://www.theallergyreport.org/professional/rhinitisO.htm 1 The Allergy Report: Stepwise approach to pharmacotherapy for seasonal and perennial allergic rhinitis.
  • ••A practical visual schema of allergic rhinitispharmacotherapy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.